Cart
sales@molnova.com
Altrenogest
CAS No. 850-52-2
Altrenogest( Altrenogest | A 35957 | A-35957 | Allyl trenbolone | DRC 6246 | R 2267 | REGU-MATE )
Catalog No. M16177 CAS No. 850-52-2
Altrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 41 | In Stock |
|
| 100MG | 58 | In Stock |
|
| 200MG | 105 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAltrenogest
-
NoteResearch use only, not for human use.
-
Brief DescriptionAltrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.
-
DescriptionAltrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone.(In Vitro):Altrenogest (Allyltrenbolone) is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with Altrenogest (Allyltrenbolone) appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. The oil and gel Altrenogest (Allyltrenbolone) preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest (Allyltrenbolone) treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL.
-
In VitroAltrenogest (Allyltrenbolone) is a progestogen structurally related to veterinary steroid trenbolone. Treatment of embryo-recipient mares with Altrenogest (Allyltrenbolone) appears to be beneficial in extending the degree of donor-recipient synchrony required for successful embryo transfer. The oil and gel Altrenogest (Allyltrenbolone) preparations are equally effective in modulating estrous behavior and time to estrus and ovulation. Altrenogest (Allyltrenbolone) treatment started late in diestrus appears to result in a high incidence of ovulation during treatment and when luteolysis and ovulation occur during treatment; the subsequent luteal phase is frequently prolonged due to failure of regression of the CL.
-
In Vivo——
-
SynonymsAltrenogest | A 35957 | A-35957 | Allyl trenbolone | DRC 6246 | R 2267 | REGU-MATE
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorER
-
Research AreaEndocrinology
-
Indication——
Chemical Information
-
CAS Number850-52-2
-
Formula Weight310.43
-
Molecular FormulaC21H26O2
-
Purity>98% (HPLC)
-
SolubilityEthanol: 2 mg/mL (6.44 mM); DMSO: 62 mg/mL (199.72 mM)
-
SMILESC[C@@]12[C@@](CC=C)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CCC4=C3C=C2)=O
-
Chemical Name(8S,13S,14S,17R)-17-allyl-17-hydroxy-13-methyl-1,2,6,7,8,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Squires EL, et al. J Anim Sci, 1983, 56(4), 901-910.
molnova catalog
related products
-
XR 5944
XR 5944 is an antitumor compound that targets DNA, is a topoisomerase inhibitor, inhibits ER activity, and can be used to study colon and lung cancer.
-
Endoxifen
A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer.
-
LSZ102
LSZ102 is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) with ERα transcription IC50 of 6 nM and ERα degradation IC50 of 0.2 nM.
